Acarbose vs Miglitol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Alpha-glucosidase · full Type 2 Diabetes pipeline
Acarbose · Precose / Glucobay
Rights held by Bayer; US product discontinued
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Miglitol · Glyset
Rights held by Bayer and partners
NCT00213070 · Phase 3 · completed
The study was randomized and double-blind, but the registry does not clearly identify a comparator arm, sample size, or primary endpoint. Because no results are posted, it is not possible to determine whether the primary glycemic endpoint was met.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Acarbose | Miglitol |
|---|---|---|
| HbA1c, change | -0.8% vs -0.1%−0.6 vs placeboNCT01177384 | —Not posted · NCT00380822 |
| Body weight, change (kg) | —Not posted · NCT01010100 | —Not posted · NCT00380822 |
| HbA1c below 7% | —Not posted · NCT01010100 | —Not posted · NCT00380822 |
| Fasting plasma glucose, change | -1.0 vs -0.2−0.8 vs placeboNCT01177384 | —Not posted · NCT00380822 |
| 3-point MACE (% with event) | —Not posted · NCT01010100 | —Not posted · NCT00380822 |
HbA1c, change
- Acarbose
- -0.8% vs -0.1%−0.6 vs placeboNCT01177384
- Miglitol
- —Not posted · NCT00380822
Body weight, change (kg)
- Acarbose
- —Not posted · NCT01010100
- Miglitol
- —Not posted · NCT00380822
HbA1c below 7%
- Acarbose
- —Not posted · NCT01010100
- Miglitol
- —Not posted · NCT00380822
Fasting plasma glucose, change
- Acarbose
- -1.0 vs -0.2−0.8 vs placeboNCT01177384
- Miglitol
- —Not posted · NCT00380822
3-point MACE (% with event)
- Acarbose
- —Not posted · NCT01010100
- Miglitol
- —Not posted · NCT00380822
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Miglitol: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Acarbose: 3 of 4 rows · Miglitol: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Acarbose |
|---|---|
| Dropout rate | 7.3%a NCT01177384 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%a NCT01177384 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 5.2%a NCT01177384 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Acarbose
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acarbose's landscape · Miglitol's landscape